Updated results of a randomized, double-blind, multicenter sham-controlled trial of microwave thermotherapy with the Dornier Urowave in patients with symptomatic benign prostatic hyperplasia

John Trachtenberg, Claus Roehrborn

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A total of 220 patients with clinical benign prostatic hyperplasia (BPH), an AUA symptom index (AUA SI) of >13 points, and a peak flow rate of <12ml/s were randomly assigned to either active or sham treatment. All treatments were conducted as an outpatient procedure without general anesthesia. Shamtreated patients underwent a simulated 60-min treatment with an indwelling treatment catheter. Patients were followed at 1 week and at 1, 3, and 6 months. The treatments were well tolerated. The AUA SI dropped from 23.6 to 12.6 points at 6 months (P < 0.05) in the active group and from 23.9 to 17.9 points in the shamtreated group (P < 0.05 for the difference between groups). There was a significant difference between the groups at 6 months (P < 0.001). Similar and statistically significant changes occurred regarding the AUA bother index and the quality of life scores. Statistically significant improvements were also noted for the peak flow rate (from 7.7 to 10.6 ml/s at 6 months for the active group and from 8.1 to 9.6 ml/s for the shamtreated group; P < 0.05 for the difference between groups) and for the average flow rate. An improvement in the AUA SI of >30% was achieved by 72% versus 40% (active versus sham) and an improvement of >50% was accomplished by 48% versus 21% of the respective patients. Actively treated patients reported more dysuria, urgency, and ejaculatory dysfunction following treatment than did sham-treated patients. Urinary retention occurred in 5.4% of patients. The Dornier Urowave is better in improving symptoms, bother, quality of life, and flow rates than is a sham treatment in patients with symptomatic BPH. The treatments can be given on an outpatient basis with local anesthesia. Adverse events are in general transient and mild in nature. This device compares favorably with other second-generation devices. Extended follow-up is necessary to document the long-term durability of these improvements.

Original languageEnglish (US)
Pages (from-to)102-108
Number of pages7
JournalWorld Journal of Urology
Volume16
Issue number2
StatePublished - 1998

Fingerprint

Induced Hyperthermia
Prostatic Hyperplasia
Microwaves
Placebos
Dysuria
Equipment and Supplies
Urinary Retention
Local Anesthesia
Outpatients
Quality of Life

ASJC Scopus subject areas

  • Urology

Cite this

@article{e1aef810b7034333926f492c35b3d482,
title = "Updated results of a randomized, double-blind, multicenter sham-controlled trial of microwave thermotherapy with the Dornier Urowave in patients with symptomatic benign prostatic hyperplasia",
abstract = "A total of 220 patients with clinical benign prostatic hyperplasia (BPH), an AUA symptom index (AUA SI) of >13 points, and a peak flow rate of <12ml/s were randomly assigned to either active or sham treatment. All treatments were conducted as an outpatient procedure without general anesthesia. Shamtreated patients underwent a simulated 60-min treatment with an indwelling treatment catheter. Patients were followed at 1 week and at 1, 3, and 6 months. The treatments were well tolerated. The AUA SI dropped from 23.6 to 12.6 points at 6 months (P < 0.05) in the active group and from 23.9 to 17.9 points in the shamtreated group (P < 0.05 for the difference between groups). There was a significant difference between the groups at 6 months (P < 0.001). Similar and statistically significant changes occurred regarding the AUA bother index and the quality of life scores. Statistically significant improvements were also noted for the peak flow rate (from 7.7 to 10.6 ml/s at 6 months for the active group and from 8.1 to 9.6 ml/s for the shamtreated group; P < 0.05 for the difference between groups) and for the average flow rate. An improvement in the AUA SI of >30{\%} was achieved by 72{\%} versus 40{\%} (active versus sham) and an improvement of >50{\%} was accomplished by 48{\%} versus 21{\%} of the respective patients. Actively treated patients reported more dysuria, urgency, and ejaculatory dysfunction following treatment than did sham-treated patients. Urinary retention occurred in 5.4{\%} of patients. The Dornier Urowave is better in improving symptoms, bother, quality of life, and flow rates than is a sham treatment in patients with symptomatic BPH. The treatments can be given on an outpatient basis with local anesthesia. Adverse events are in general transient and mild in nature. This device compares favorably with other second-generation devices. Extended follow-up is necessary to document the long-term durability of these improvements.",
author = "John Trachtenberg and Claus Roehrborn",
year = "1998",
language = "English (US)",
volume = "16",
pages = "102--108",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Updated results of a randomized, double-blind, multicenter sham-controlled trial of microwave thermotherapy with the Dornier Urowave in patients with symptomatic benign prostatic hyperplasia

AU - Trachtenberg, John

AU - Roehrborn, Claus

PY - 1998

Y1 - 1998

N2 - A total of 220 patients with clinical benign prostatic hyperplasia (BPH), an AUA symptom index (AUA SI) of >13 points, and a peak flow rate of <12ml/s were randomly assigned to either active or sham treatment. All treatments were conducted as an outpatient procedure without general anesthesia. Shamtreated patients underwent a simulated 60-min treatment with an indwelling treatment catheter. Patients were followed at 1 week and at 1, 3, and 6 months. The treatments were well tolerated. The AUA SI dropped from 23.6 to 12.6 points at 6 months (P < 0.05) in the active group and from 23.9 to 17.9 points in the shamtreated group (P < 0.05 for the difference between groups). There was a significant difference between the groups at 6 months (P < 0.001). Similar and statistically significant changes occurred regarding the AUA bother index and the quality of life scores. Statistically significant improvements were also noted for the peak flow rate (from 7.7 to 10.6 ml/s at 6 months for the active group and from 8.1 to 9.6 ml/s for the shamtreated group; P < 0.05 for the difference between groups) and for the average flow rate. An improvement in the AUA SI of >30% was achieved by 72% versus 40% (active versus sham) and an improvement of >50% was accomplished by 48% versus 21% of the respective patients. Actively treated patients reported more dysuria, urgency, and ejaculatory dysfunction following treatment than did sham-treated patients. Urinary retention occurred in 5.4% of patients. The Dornier Urowave is better in improving symptoms, bother, quality of life, and flow rates than is a sham treatment in patients with symptomatic BPH. The treatments can be given on an outpatient basis with local anesthesia. Adverse events are in general transient and mild in nature. This device compares favorably with other second-generation devices. Extended follow-up is necessary to document the long-term durability of these improvements.

AB - A total of 220 patients with clinical benign prostatic hyperplasia (BPH), an AUA symptom index (AUA SI) of >13 points, and a peak flow rate of <12ml/s were randomly assigned to either active or sham treatment. All treatments were conducted as an outpatient procedure without general anesthesia. Shamtreated patients underwent a simulated 60-min treatment with an indwelling treatment catheter. Patients were followed at 1 week and at 1, 3, and 6 months. The treatments were well tolerated. The AUA SI dropped from 23.6 to 12.6 points at 6 months (P < 0.05) in the active group and from 23.9 to 17.9 points in the shamtreated group (P < 0.05 for the difference between groups). There was a significant difference between the groups at 6 months (P < 0.001). Similar and statistically significant changes occurred regarding the AUA bother index and the quality of life scores. Statistically significant improvements were also noted for the peak flow rate (from 7.7 to 10.6 ml/s at 6 months for the active group and from 8.1 to 9.6 ml/s for the shamtreated group; P < 0.05 for the difference between groups) and for the average flow rate. An improvement in the AUA SI of >30% was achieved by 72% versus 40% (active versus sham) and an improvement of >50% was accomplished by 48% versus 21% of the respective patients. Actively treated patients reported more dysuria, urgency, and ejaculatory dysfunction following treatment than did sham-treated patients. Urinary retention occurred in 5.4% of patients. The Dornier Urowave is better in improving symptoms, bother, quality of life, and flow rates than is a sham treatment in patients with symptomatic BPH. The treatments can be given on an outpatient basis with local anesthesia. Adverse events are in general transient and mild in nature. This device compares favorably with other second-generation devices. Extended follow-up is necessary to document the long-term durability of these improvements.

UR - http://www.scopus.com/inward/record.url?scp=0032396519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032396519&partnerID=8YFLogxK

M3 - Article

C2 - 12080961

AN - SCOPUS:0032396519

VL - 16

SP - 102

EP - 108

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 2

ER -